Catalytic process for preparing an α,β-ethylenically unsaturated carboxylic acid salt, comprising reacting an alkene and carbon dioxide in the presence of a carboxylation catalyst and releasing the α,β-ethylenically unsaturated carboxylic acid salt with a base, the carboxylation catalyst being a transition metal complex, which comprises a structurally constrained bidentate P,X ligand, wherein X is selected from the group consisting of P, N, O, and carbene, the P and X atom are separated by 2 to 4 bridging atoms, and wherein the bridging atoms are part of at least one 5- to 7-membered cyclic substructure. A further catalytic processes for preparing α-βethylenically unsaturated carboxylic acid derivatives from CO.sub.2 and an alkene is provided.

The present invention is directed to reaction mixtures comprising a water-surfactant mixture, wherein the catalyst comprises a compound with solubilizing groups. This technology improves the solubility of the reaction components in the water-surfactant mixture and thereby, greatly increases the productivity and selectivity of the chemical reaction.

A process of converting a carbon-carbon multiple bond to a cyclopropane ring, comprising the addition of a N-alkyl-N-nitroso compound to a mixture of alkene precursor, aqueous base and Pd(II)-catalyst, with the N-alkyl-N-nitroso compound obtained directly from an alkyl amine derivative, NaNO.sub.2 and an acid via phase separation of the N-alkyl-N-nitroso compound from the aqueous phase.

An ink composition, including a quantum dot; a metal catalyst; an aromatic halide compound; an ene compound including at least one C—H moiety and a carbon-carbon unsaturated bond; and optionally, a metal oxide particle, wherein the metal catalyst is a metal salt, a metal coordination complex, or a combination thereof, wherein the metal catalyst comprises a metal that is palladium, nickel, ruthenium, rhodium, iridium, iron, cobalt, chromium, copper, platinum, silver, gold, or a combination thereof.

Methods of synthesizing the angiotensin II receptor antagonist telmisartan in high yield and purity are provided. The methods involve the coupling of two structurally distinct benzimidazole units via a Suzuki cross-coupling reaction. Methods of regioselectively synthesizing one of the benzimidazole units are also provided.

A catalyst system includes a transition metal salt containing a halo group, an acetate group, or a combination thereof, and an organic phosphine ligand. The molar ratio of the organic phosphine ligand to the transition metal salt is greater than 0 and less than or equal to 50.

The invention relates to polyoxometalates represented by the formula (A.sub.n).sup.m+[M′M.sub.12O.sub.y(RCOO).sub.zH.sub.q].sup.m− or solvates thereof, corresponding supported polyoxometalates, and processes for their preparation, as well as corresponding metal clusters, optionally in the form of a dispersion in a liquid carrier medium or immobilized on a solid support, and processes for their preparation, as well as their use in reductive conversion of organic substrate.

The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.

Phosphine phosphonate and phenoxyphosphine ligands bearing polyethylene glycol (PEG) chains are used as described herein to produce heterobimetallic catalysts. The ligands can be metallated selectively with palladium or nickel and secondary metal ions to provide well-defined heterobimetallic compounds. These heterobimetallic complexes exhibit accelerated reaction rates and greater thermal stability in olefin polymerization compared to other catalysts.

A method of preparing Compound (1) or a pharmaceutically acceptable salt thereof: ##STR00001##
comprises: (a) reacting Compound (X): ##STR00002##
or a pharmaceutically acceptable salt thereof with Compound (Y): ##STR00003##
in the presence of a palladium catalyst and a carbonate or phosphate base to form compound (Z): ##STR00004##
or a pharmaceutically acceptable salt thereof; and (b) deprotecting the Ts group of Compound (Z) to form Compound (1) or a pharmaceutically acceptable salt thereof.